Seres Therapeutics financials
$3.48−1.14%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $789.0K | $0.00 | $0.00 | $0.00 | $144.9M | $33.2M | $34.5M | $28.3M | $32.1M | $21.8M |
| Gross profit | $789.0K | $0.00 | $0.00 | $0.00 | $144.9M | $33.2M | $34.5M | $28.3M | $32.1M | $21.8M |
| Gross margin | 100.0% | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$94.0M | -$121.3M | -$195.1M | -$179.9M | -$64.5M | -$88.1M | -$71.9M | -$100.3M | -$91.4M | -$92.8M |
| Net income | $5.7M | $136.0K | -$113.7M | -$250.2M | -$65.6M | -$89.1M | -$70.3M | -$98.9M | -$89.4M | -$91.6M |
| Net margin | 721.9% | — | — | — | −45.2% | −268.3% | −203.7% | −350.0% | −278.4% | −420.7% |
| Diluted EPS | $0.64 | $0.00 | $-17.77 | $-46.20 | $-14.40 | $-22.40 | $-24.80 | $-48.60 | $-44.20 | $-46.00 |
| EBITDA | -$89.8M | -$115.8M | -$188.9M | -$173.3M | -$58.5M | -$81.6M | -$62.8M | -$92.4M | -$84.1M | -$88.6M |
| Operating cash flow | $1.1M | -$148.6M | -$117.4M | -$228.8M | $6.7M | -$93.6M | -$76.5M | -$62.9M | -$75.5M | $43.9M |
| Free cash flow | $865.0K | -$149.0M | -$125.3M | -$238.6M | -$2.9M | -$94.2M | -$77.5M | -$64.8M | -$80.2M | $22.4M |
| Diluted shares | 8.9M | 7.8M | 6.4M | 5.4M | 4.6M | 4.0M | 2.8M | 2.0M | 2.0M | 2.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $45.8M | $30.8M | $128.0M | $163.0M | $180.0M | $116.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $18.3M | $110.7M | $137.6M |
| Total debt | $0.00 | $0.00 | $101.5M | $51.0M | $24.6M | $25.1M |
| Total assets | $138.2M | $139.8M | $358.6M | $348.8M | $354.9M | $342.9M |
| Total liabilities | $94.0M | $126.0M | $403.5M | $338.0M | $223.4M | $168.2M |
| Shareholders' equity | $44.2M | $13.8M | -$44.9M | $10.8M | $131.5M | $174.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology